Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552048 | 1.00 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6552050 | 1.00 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6552194 | 1.00 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6552508 | 1.00 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6552199 | 0.93 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6552494 | 0.93 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6553407 | 0.93 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6553404 | 0.93 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6553075 | 0.93 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6552031 | 0.93 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171416-B1 | 3-BICYCLOARYL-2-AMINOMETHYL BICYCLOALKANES AS SEROTONINE REUPTAKE INHIBITORS | LILLY CO ELI (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-6384281-B1 | USED IN TREATING NERVOUS SYSTEM DISORDERS E.G DEPRESSION, ALCOHOLISM, PAIN, HYPERTENSION, ALZHEIMER'S, MEMORY LOSS, ATTENTION-DEFICIT/OBSESSIVE COMPULSIVE/GASTRIC/CARDIOVASCULAR DISORDERS, PARKINSON'S, ANXIETY, CHRONIC FATIGUE SYNDROME, | ELI LILLY AND COMPANY | 2002-05-07 | — | — | US | disclosed |